Table 2.

COVID-19 severity and development of thrombotic/cardiovascular disease among study patients with or without antithrombotic treatment

Thrombotic/cardiovascular disease characteristics	Overall study population (n = 9282)	With antithrombotic treatment (n = 3312)	Without antithrombotic treatment (n = 5970)	P value
Thrombotic/cardiovascular disease, n (%)
Deep venous thromboembolism	247 (2.7)	224 (6.8)	23 (0.4)	< 0.0001
Pulmonary embolism	64 (0.7)	58 (1.8)	6 (0.1)	< 0.0001
Systemic embolism	86 (0.9)	77 (2.3)	9 (0.2)	< 0.0001
Ischemic stroke/TIA	243 (2.6)	210 (6.3)	33 (0.6)	< 0.0001
Myocardial infarction/ACS	207 (2.2)	179 (5.4)	28 (0.5)	< .0001
Chronic ischemic heart disease	192 (2.1)	166 (5.0)	26 (0.4)	< 0.0001
Duplication of outcome thrombotic/cardiovascular disease, n (%)				< .0001
Patients with 1 event	612 (6.6)	524 (15.8)	88 (1.5)
Patients with 2 events	171 (1.8)	152 (4.6)	19 (0.32)
Patients with 3 events	21 (0.23)	21 (0.63)	0 (0)
Patients with 4 events	4 (0.04)	4 (0.12)	0 (0)
COVID-19 severity, n (%)				< 0.0001
Not severe	7278 (78.4)	2453 (74.1)	4825 (80.8)
Severe	2004 (21.6)	859 (25.9)	1145 (19.2)
Procedure usage
Duration of hospitalization (days), mean ± SD	15 ± 14	20 ± 19	12 ± 10	< 0.0001
ECMO, n (%)	24 (0.26)	24 (0.73)	0 (0)	< 0.0001
Mechanical ventilation, n (%)	386 (4.2)	324 (9.8)	62 (1.0)	< 0.0001
Oxygen therapy, n (%)	3110 (33.5)	1762 (53.2)	1348 (22.6)	< 0.0001
ICU, n (%)	1792 (19.3)	695 (21.0)	1097 (18.4)	0.0023
Length of ICU stay (days), mean ± SD	6.6 ± 7.8	8.2 ± 9.0	3.7 ± 3.2	< 0.0001
In-hospital death, n (%)	505 (5.4)	300 (9.1)	205 (3.4)	< 0.0001

ASC Acute coronary syndrome, COVID-19 coronavirus disease 2019, ECMO extracorporeal membrane oxygenation, ICU intensive care unit, n number of patients, TIA transient ischemic attack